Literature DB >> 29432525

Factors influencing the use of subcutaneous or transvenous implantable cardioverter-defibrillators: results of the European Heart Rhythm Association prospective survey.

Serge Boveda1, Radoslaw Lenarczyk2, Stefano Fumagalli3, Roland Tilz4, Kinga Goscinska-Bis5, Maciej Kempa6, Pascal Defaye7, Christelle Marquié8, Alessandro Capucci9, Laura Ueberham10, Nikolaos Dagres10.   

Abstract

The purpose of this European Heart Rhythm Association (EHRA) prospective snapshot survey is to provide an overview of the factors influencing patient selection for the implantation of a particular type of device: subcutaneous implantable cardioverter-defibrillator (S-ICD) or transvenous implantable cardioverter-defibrillator (TV-ICD), across a broad range of tertiary European centres. A specially designed electronic questionnaire was sent via the internet to tertiary reference centres routinely implanting both TV-ICDs and S-ICDs. These centres were asked to prospectively include and fill-in this questionnaire for all consecutive patients implanted with an implantable cardioverter-defibrillator (ICD) (both TV-ICD and S-ICD) during an 8-week period of time. Questions concerned standards of care and policies used for patient management, focusing particularly on the reasons for choosing one or the other type of ICD for each patient. In total 20 centres participated at the survey and entered individual data from a total of 429 consecutive patients (men 76.3%). Indication of implantation was primary prevention for 73% of the patients. Implanted devices were distributed between cardiac resynchronisation therapy (CRT) ones with back-up defibrillators (31.6%), single-chamber TV-ICD (29.5%), S-ICD (19.8%), and dual-chamber TV-ICD (19.1%).The rate of S-ICD shows the current penetration of this treatment in everyday practice. Main reasons favouring the use of an S-ICD were young age (66.7%), anticipated (38.9%) or previous (9.3%) lead-related complications, and elevated risk (18.5%) or previous device infection (7.4%). Importantly, the choice for this device was also based on patient preference (16.7%) or active lifestyle (13%). The three most frequent reasons for the use of a transvenous device were the option of antitachycardia pacing (43.2%), and logically, the current or expected need for CRT (40%) or for permanent pacing (39.6%). This snapshot survey with individual patient data provides a contemporary insight into ICD implantation and management in the European electrophysiology tertiary centres. It also helps to better understand the reasons which condition the choice between a S-ICD and a traditional TV-ICD. Finally, it gives a picture of the distribution of various types of ICD, few years after the introduction of the S-ICD in the Europe.

Entities:  

Mesh:

Year:  2018        PMID: 29432525     DOI: 10.1093/europace/euy009

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  3 in total

1.  Initial experience with the subcutaneous implantable cardioverter-defibrillator with the real costs of hospitalization analysis in a single Polish center.

Authors:  Marcin Grabowski; Monika Gawałko; Marcin Michalak; Andrzej Cacko; Michał Kowara; Agnieszka Kołodzińska; Łukasz Januszkiewicz; Paweł Balsam; Laura Vitali Serdoz; Joachim Winter; Grzegorz Opolski
Journal:  Cardiol J       Date:  2018-04-03       Impact factor: 2.737

2.  Multicentre experience with the second-generation subcutaneous implantable cardioverter defibrillator and the intermuscular two-incision implantation technique.

Authors:  Federico Migliore; Giulia Mattesi; Pietro De Franceschi; Giuseppe Allocca; Martino Crosato; Vittorio Calzolari; Mauro Fantinel; Benedetta Ortis; Domenico Facchin; Elisabetta Daleffe; Tommaso Fabris; Elena Marras; Manuel De Lazzari; Francesco Zanon; Lina Marcantoni; Mariachiara Siciliano; Domenico Corrado; Sabino Iliceto; Emanuele Bertaglia; Massimo Zecchin
Journal:  J Cardiovasc Electrophysiol       Date:  2019-03-13

3.  Utilization of Subcutaneous Cardioverter-Defibrillator in Poland and Europe-Comparison of the Results of Multi-Center Registries.

Authors:  Maciej Kempa; Andrzej Przybylski; Szymon Budrejko; Tomasz Fabiszak; Michał Lewandowski; Krzysztof Kaczmarek; Mateusz Tajstra; Marcin Grabowski; Przemysław Mitkowski; Stanisław Tubek; Ewa Jędrzejczyk-Patej; Radosław Lenarczyk; Dariusz Jagielski; Janusz Romanek; Anna Rydlewska; Zbigniew Orski; Joanna Zakrzewska-Koperska; Artur Filipecki; Marcin Janowski; Tatjana Potpara; Serge Boveda
Journal:  Int J Environ Res Public Health       Date:  2021-07-05       Impact factor: 3.390

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.